Michael Yee
Stock Analyst at Jefferies
(2.71)
# 1,924
Out of 4,847 analysts
82
Total ratings
41.07%
Success rate
6.65%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Initiates: Buy | $135 | $127.79 | +5.64% | 1 | Mar 17, 2025 | |
| ALXO ALX Oncology Holdings | Upgrades: Buy | $2 → $3 | $0.56 | +436.96% | 5 | Mar 6, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Hold | $32 → $3 | $4.29 | -30.07% | 3 | Jan 30, 2025 | |
| KOD Kodiak Sciences | Upgrades: Buy | $20 | $3.60 | +456.33% | 3 | Dec 9, 2024 | |
| BIIB Biogen | Downgrades: Hold | $250 → $180 | $131.14 | +37.26% | 5 | Dec 9, 2024 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Buy | $500 → $550 | $445.43 | +23.48% | 4 | Dec 9, 2024 | |
| AMGN Amgen | Maintains: Buy | $380 | $288.47 | +31.73% | 5 | Nov 12, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $40 → $45 | $13.96 | +222.35% | 2 | Nov 1, 2024 | |
| MRNA Moderna | Maintains: Hold | $65 → $55 | $27.05 | +103.33% | 8 | Oct 15, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $35 | $13.05 | +168.20% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $11.77 | +239.85% | 1 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $385 | $758.57 | -49.25% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1.4 → $10 | $2.34 | +327.35% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $1.87 | +60.43% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $75 → $30 | $16.19 | +85.30% | 2 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $60 → $20 | $11.79 | +69.64% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 → $20 | $29.77 | -32.82% | 3 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 → $75 | $5.21 | +1,339.54% | 1 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $2.04 | +1,370.59% | 1 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $38.65 | +68.18% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $75 → $45 | $0.29 | +15,216.54% | 2 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $0.92 | +3,165.84% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $4.66 | +543.78% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $15.25 | +686.89% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $70 → $75 | $21.69 | +245.78% | 2 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $13.01 | +130.59% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $4.84 | +1,490.91% | 2 | Nov 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $108.91 | - | 3 | Jan 26, 2018 |
Blueprint Medicines
Mar 17, 2025
Initiates: Buy
Price Target: $135
Current: $127.79
Upside: +5.64%
ALX Oncology Holdings
Mar 6, 2025
Upgrades: Buy
Price Target: $2 → $3
Current: $0.56
Upside: +436.96%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Hold
Price Target: $32 → $3
Current: $4.29
Upside: -30.07%
Kodiak Sciences
Dec 9, 2024
Upgrades: Buy
Price Target: $20
Current: $3.60
Upside: +456.33%
Biogen
Dec 9, 2024
Downgrades: Hold
Price Target: $250 → $180
Current: $131.14
Upside: +37.26%
Vertex Pharmaceuticals
Dec 9, 2024
Upgrades: Buy
Price Target: $500 → $550
Current: $445.43
Upside: +23.48%
Amgen
Nov 12, 2024
Maintains: Buy
Price Target: $380
Current: $288.47
Upside: +31.73%
Denali Therapeutics
Nov 1, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $13.96
Upside: +222.35%
Moderna
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $27.05
Upside: +103.33%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $13.05
Upside: +168.20%
Sep 13, 2024
Initiates: Buy
Price Target: $40
Current: $11.77
Upside: +239.85%
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $758.57
Upside: -49.25%
Mar 27, 2024
Upgrades: Buy
Price Target: $1.4 → $10
Current: $2.34
Upside: +327.35%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $1.87
Upside: +60.43%
Dec 8, 2023
Downgrades: Hold
Price Target: $75 → $30
Current: $16.19
Upside: +85.30%
Oct 25, 2023
Downgrades: Hold
Price Target: $60 → $20
Current: $11.79
Upside: +69.64%
Oct 25, 2023
Upgrades: Buy
Price Target: $8 → $20
Current: $29.77
Upside: -32.82%
Jan 6, 2023
Upgrades: Buy
Price Target: $63 → $75
Current: $5.21
Upside: +1,339.54%
Nov 15, 2021
Initiates: Buy
Price Target: $30
Current: $2.04
Upside: +1,370.59%
Mar 2, 2021
Initiates: Buy
Price Target: $65
Current: $38.65
Upside: +68.18%
Mar 2, 2021
Downgrades: Hold
Price Target: $75 → $45
Current: $0.29
Upside: +15,216.54%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $0.92
Upside: +3,165.84%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $4.66
Upside: +543.78%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $15.25
Upside: +686.89%
Oct 12, 2020
Upgrades: Buy
Price Target: $70 → $75
Current: $21.69
Upside: +245.78%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $13.01
Upside: +130.59%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $4.84
Upside: +1,490.91%
Jan 26, 2018
Upgrades: Buy
Price Target: n/a
Current: $108.91
Upside: -